Hans Torrenga
VU University Amsterdam
Network
Latest external collaboration on country level. Dive into details by clicking on the dots.
Publication
Featured researches published by Hans Torrenga.
Histopathology | 1999
P. J. van Diest; Hans Torrenga; Paul J. Borgstein; Rik Pijpers; R.P. Bleichrodt; Frans D. Rahusen; S. Meijer
The sentinel lymph node procedure enables selective targeting of the first draining lymph node, where the initial metastases will form. A negative sentinel node (SN) predicts the absence of tumour metastases in the other regional lymph nodes with high accuracy. This means that in the case of a negative SN, regional lymph node dissection is no longer necessary. Besides saving costs, this will prevent many side‐effects of lymph node dissection. The aim of this study was to evaluate the reliability of intraoperative cytological and frozen section investigation of the SN to detect metastases. This would allow the axillary lymph node dissection to be performed in the same session as the SN procedure and the excision of the primary tumour in case of a positive SN.
Journal of Clinical Pathology | 2004
W E Mesker; Hans Torrenga; W C R Sloos; H Vrolijk; R A E M Tollenaar; P. C. De Bruin; P. J. van Diest; H J Tanke
Aims: To investigate the practicality and sensitivity of supervised automated microscopy (AM) for the detection of micrometastasis in sentinel lymph nodes (SLNs) from patients with breast carcinoma. Methods: In total, 440 SLN slides (immunohistochemically stained for cytokeratin) from 86 patients were obtained from two hospitals. Samples were selected on the basis of: (1) a pathology report mentioning micrometastases or isolated tumour cells (ITCs) and (2) reported as negative nodes (N0). Results: From a test set of 29 slides (12 SLN positive patients, including positive and negative nodes), 18 slides were scored positive by supervised AM and 11 were negative. Routine examination revealed 17 positive slides and 12 negative. Subsequently, automated reanalysis of 187 slides (34 patients; institute I) and 216 slides (40 patients; institute II) from reported node negative (N0) patients showed that two and seven slides (from two and five patients, respectively) contained ITCs, respectively, all confirmed by the pathologists, corresponding to 5.9% and 12.5% missed patients. In four of the seven missed cases from institute II, AM also detected clusters of four to 30 cells, but all with a size ⩽ 0.2 mm. Conclusions: Supervised AM is a more sensitive method for detecting immunohistochemically stained micrometastasis and ITCs in SLNs than routine pathology. However, the clinical relevance of detecting cytokeratin positive cells in SLNs of patients with breast cancer is still an unresolved issue and is at the moment being validated in larger clinical trials.
Annals of Surgical Oncology | 2004
Hans Torrenga; Sybren Meijer; Hans Fabry; Joost van der Sijp
Since its introduction in the early 1990s, the sentinel node (SN) concept in breast cancer has been validated by many studies. Because SN biopsy in breast cancer enables the identification of node-negative axillae, the potential morbidity of an axillary lymph node dissection (ALND) can be avoided. The SN procedure is still surrounded by many variables and uncertainties, such as the clinical relevance of micrometastases. However, the main goal is to avoid unnecessary ALND in node-negative breast cancer patients. Sufficient clinical data are available to achieve this goal by incorporating the SN procedure into routine clinical practice. The ultimate safety of the applied technique will be determined by the number of axillary recurrences during long-term follow-up. Preoperative lymphoscintigraphy and intraoperative use of both blue dye and a hand-held gamma probe—the triple technique—has been applied at our institute since early 1994.
Archives of Surgery | 2001
Frans D. Rahusen; Hans Torrenga; Paul J. van Diest; Rik Pijpers; Elsken van der Wall; Jappe Licht; Sybren Meijer
Surgery | 2000
Frans D. Rahusen; Rik Pijpers; Paul J. van Diest; R.P. Bleichrodt; Hans Torrenga; Sybren Meijer
Journal of Clinical Pathology | 2001
Hans Torrenga; Frans D. Rahusen; S. Meijer; Paul J. Borgstein; P. J. van Diest
Journal of Surgical Oncology | 2004
Hans Torrenga; Hans Fabry; Joost R.M. van der Sijp; Paul J. van Diest; Rik Pijpers; Sybren Meijer
Seminars in Surgical Oncology | 2001
Paul J. van Diest; Hans Torrenga; Sybren Meijer; Chris J. L. M. Meijer
Nederlands Tijdschrift voor Geneeskunde | 2002
S. Meijer; Hans Torrenga; J. R. M. Van Der Sijp
Journal of the National Cancer Institute | 2001
Hans Torrenga; Jappe Licht; Jacobus J. M. van der Hoeven; Otto S. Hoekstra; Sybren Meijer; Paul J. van Diest